LXRX - Lexicon gains as diabetes therapy undergoes FDA review
2024-07-16 10:02:02 ET
More on Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
- Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
- Lexicon appoints Mike Exton as CEO, Jeff Wade as COO
- Lexicon resubmits FDA application for sotagliflozin for type 1 diabetes
- Seeking Alpha’s Quant Rating on Lexicon Pharmaceuticals